The Hellenic Journal of Cardiology, a peer-reviewed open-access publication under the esteemed ELSEVIER banner, proudly represents the forefront of research in the field of Cardiology and Cardiovascular Medicine. Established in 1993 and actively publishing since then, this journal has carved a niche in disseminating high-quality research and clinical insights relevant to cardiovascular health in Greece and beyond. With an impressive Q2 ranking in both Cardiology and Cardiovascular Medicine categories as of 2023, the journal holds a commendable position at Rank #126/387 in Scopus, indicative of its critical role in advancing scientific knowledge and practice. The Hellenic Journal of Cardiology transitioned to open access in 2016, ensuring that ground-breaking research is freely accessible, fostering a global dialogue among researchers, clinicians, and students alike. Its publication frequency spans significant years, providing a continuous flow of innovative findings while addressing pressing cardiovascular issues. As the journal builds on its legacy, it aspires to enrich the academic community's understanding of cardiovascular medicine, making it an invaluable resource for anyone invested in heart health.

ACTA CARDIOLOGICA is a distinguished journal published by TAYLOR & FRANCIS LTD, focusing on the dynamic fields of Cardiology and Cardiovascular Medicine. Established in 1946, the journal has maintained a significant presence in the academic community, providing a platform for cutting-edge research and clinical studies that aim to address challenges in cardiovascular health. With its Q3 rating in both Cardiology and General Medicine categories, it showcases a robust compilation of articles that reflect the evolving landscape of cardiac care. Although ACTA CARDIOLOGICA is not an Open Access journal, it continues to serve a vital role for researchers, professionals, and students dedicated to advancing knowledge in cardiovascular health. This journal, with an ISSN of 0001-5385 and E-ISSN of 1784-973X, is a critical resource for those looking to stay updated on the latest developments and practices in the specialization, contributing significantly to the field until 2024 and beyond.

Catheterization and Cardiovascular Interventions is a leading peer-reviewed journal published by Wiley, dedicated to advancing the fields of cardiology, cardiovascular medicine, and radiology. With an impressive impact factor and categorized in the Q1 quartile across multiple disciplines—including Cardiology, Medicine, and Radiology—this journal serves as an essential resource for researchers, clinicians, and students interested in the latest developments in minimally invasive techniques and innovative cardiovascular therapies. Since its inception in 1999 and continuing through 2024, Catheterization and Cardiovascular Interventions has provided a platform for high-quality original research, reviews, and case studies, highlighting approaches that improve patient outcomes and treatment methodologies. Operating from the United States, the journal offers various access options, making key findings in cardiovascular interventions readily available to its audience. Stay at the forefront of cardiovascular innovation by engaging with this pivotal publication.

Cardiovascular Diabetology is a prestigious open-access journal published by BMC, focusing on the intersecting fields of cardiology, endocrinology, diabetes, and internal medicine. Since its inception in 2002, this journal has established itself as a vital resource for researchers, clinicians, and academics dedicated to advancing knowledge in these areas. With an impressive impact factor reflected in its Q1 rankings for the year 2023 across its respective categories, including a ranking of 22nd in Cardiology and Cardiovascular Medicine and notably 15th in Internal Medicine, it positions itself at the forefront of scholarly communication. The journal encourages the dissemination and sharing of groundbreaking research, providing open access to foster engagement and collaboration among professionals globally. As it converges from 2002 to 2024, Cardiovascular Diabetology continues to be a pivotal platform for innovative studies, reviews, and critical insights that significantly impact clinical practices and medical education in the evolving landscape of cardiovascular health and diabetes management.

Korean Circulation Journal, published by the Korean Society of Cardiology, has established itself as a prominent platform for disseminating research in the fields of Cardiology and Cardiovascular Medicine. With an ISSN of 1738-5520 and an E-ISSN of 1738-5555, this journal has been at the forefront of cardiovascular science since its inception in 2006 and is projected to continue until 2024. The journal's commitment to quality is reflected in its 2023 category quartiles, ranking in the second quartile (Q2) for both Cardiology and Internal Medicine, as well as its commendable Scopus rankings within the respective fields. Located in South Korea, the journal aims to bridge the gap between cutting-edge research and practical applications, serving as an invaluable resource for researchers, healthcare professionals, and students keen on advancing their understanding of cardiovascular health. Although currently not an open-access journal, it provides a wealth of knowledge that encourages evidence-based practice in clinical settings.

Cardiovascular Intervention and Therapeutics, published by SPRINGER JAPAN KK, stands as a prominent journal within the fields of cardiology and cardiovascular medicine, reflecting its commitment to disseminating groundbreaking research and clinical advances. With an impressive Q2 ranking in Cardiology and Cardiovascular Medicine as well as in Medicine (miscellaneous), and a Q1 ranking in Radiology, Nuclear Medicine and Imaging, this journal employs rigorous peer-review processes to ensure the quality and relevance of its content. Catering to a diverse audience of researchers, clinicians, and students, the journal aims to foster innovation and enhance understanding through the publication of original research, reviews, and clinical studies focused on cardiovascular interventions and therapies. Spanning over a decade of evolution from 2010 to 2024, Cardiovascular Intervention and Therapeutics continues to be a vital resource for advancing knowledge and practice in the cardiovascular field. Explore the latest advancements and insights that this esteemed journal has to offer, and contribute to the ongoing dialogue that shapes modern cardiovascular medicine.

The Journal fur Kardiologie, published by KRAUSE & PACHERNEGG GMBH, is a pivotal resource in the field of Cardiology and Cardiovascular Medicine. With an ISSN of 1024-0098 and an E-ISSN of 1680-936X, this journal has played a significant role in disseminating valuable research and clinical studies from 1998 until its coverage discontinuation in Scopus in 2017. Despite its Scopus rank being relatively low at #316/324 in its category, it continues to serve as a platform for emerging cardiology research. The journal’s scope encompasses various aspects of cardiovascular health, providing insights that are crucial for researchers, professionals, and students alike seeking to advance their knowledge and practice in cardiology. While the journal is not open access, its contributions to the field are essential for those looking to stay informed about the latest developments in cardiovascular medicine.

Netherlands Heart Journal is a premier academic publication dedicated to advancing knowledge in the field of cardiology and cardiovascular medicine. Published by BOHN STAFLEU VAN LOGHUM BV, this journal has established itself as a critical platform for researchers, professionals, and students seeking to explore groundbreaking findings and innovative practices in cardiovascular health. With an ISSN of 1568-5888 and E-ISSN 1876-6250, the journal boasts a respectable Q2 ranking in the Cardiology and Cardiovascular Medicine category, placing it in the top half of its field according to the 2023 quartiles. The Scopus ranking places it 130th out of 387 in the relevant category, indicating a commendable percentile rank of 66th, which attests to its influence and quality of published research. Spanning from 2005 to 2024, the journal endeavors to include a diverse array of topics, encompassing clinical practice, technological innovations, and public health considerations related to cardiovascular diseases. Researchers and practitioners are encouraged to engage with the journal's robust content, contributing to and benefiting from the collaborative effort to enhance cardiovascular health worldwide.

Cardiovascular Revascularization Medicine, published by Elsevier Inc, serves as a pivotal platform for research and clinical advancements in the field of cardiology and cardiovascular medicine. With an ISSN of 1553-8389 and an E-ISSN of 1878-0938, this journal has been a key resource since its inception in 2005, converging to highlight innovative approaches for cardiovascular interventions and revascularization techniques through 2024. Although it currently holds a Q3 ranking in both cardiology and general medicine categories as per the 2023 metrics, it continues to empower researchers and healthcare professionals by publishing peer-reviewed articles that bridge the gap between experimental and clinical medicine. With comprehensive coverage of emergent therapies and procedural advancements, Cardiovascular Revascularization Medicine is essential for anyone aiming to stay abreast of the evolving landscape of cardiovascular treatment. Researchers, professionals, and students alike will find invaluable insights and evidence-based research that can impact patient outcomes positively.

Journal of Cardiovascular Development and Disease, an esteemed publication by MDPI, has been a dedicated platform for disseminating cutting-edge research since its inception in 2014. Based in Switzerland, this Open Access journal not only provides unrestricted access to its content but also fosters global collaboration among scholars focusing on cardiovascular health and disease development. With an impressive focus classified as Q1 in Pharmacology, Toxicology and Pharmaceutics for 2023, it attracts a diverse range of interdisciplinary research, supporting advancements in pharmacological applications relevant to cardiac conditions. The journal's ongoing convergence through 2024 highlights its commitment to the evolving landscape of cardiovascular research, making it a vital resource for researchers, professionals, and students alike who are keen to contribute to and learn from significant developments in this critical field.